OKYO is a clinical-stage ophthalmology company developing urcosimod to treat neuropathic corneal pain (NCP). Corneal nerve damage causes NCP, a debilitating condition with no currently approved topical treatments. Urcosimod is a lipidated chemerin peptide eye drop that targets the ChemR23 receptor to reduce inflammatory signaling and nerve sensitization. As a pre-revenue business, OKYO has no commercial products and funds its operations primarily through equity raises. OKYO focuses on advancing urcosimod through the clinical pipeline toward FDA approval. OKYO recently pivoted development from dry eye disease to NCP after Phase 2 results showed significant reductions in ocular pain. OKYO is now preparing for the Phase 3 NEPTUNE clinical trial. OKYO operates under an exclusive license from On Target Therapeutics and Tufts Medical Center, which requires OKYO to pay development and sales milestones plus royalties on net sales. While OKYO maintains a secondary candidate, OK-201, management currently concentrates resources on urcosimod. OKYO positions urcosimod as a first-in-class, non-opioid prescription treatment for patients who currently rely on off-label alternatives like NSAIDs and opioids.